CytomX Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

CTMX$1.980.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders’ Equity (Deficit)

(in thousands, except share data)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income (Loss) · Deficit · Equity (Deficit)
Balance at December 31, 2024	80,099,889	$1		$691,095	$27		$(691,579)		$(456)
Exercise of stock options and release of RSUs	521,404	—		—	—		—		—
Stock-based compensation	—	—		2,008	—		—		2,008
Other comprehensive loss	—	—		—	(28)		—		(28)
Net income	—	—		—	—		23,525		23,525
Balance at March 31, 2025	80,621,293	$1		$693,103	$(1)		$(668,054)		$25,049
Exercise of stock options and release of RSUs	332,741	—		76	—		—		76
Issuance of common stock under the ESPP	110,974	—		101	—		—		101
Issuance of common stock in follow-on offering, net of issuance cost	76,923,076	1		93,372	—		—		93,373
Exercise of pre-funded warrants	6,923,031	—		—	—		—		—
Stock-based compensation			1,431			—		1,431
Other comprehensive income	—	—		—	34		—		34
Net loss	—	—		—	—		(154)		(154)
Balance at June 30, 2025	164,911,115	$2		$788,083	33		$(668,208)		119,910
Exercise of stock options	158,532	—		253	—		—		253
Stock-based compensation	—	—		1,384	—		—		1,384
Other comprehensive income	—	—		—	71		—		71
Net loss	—	—		—	—		(14,229)		(14,229)
Balance at September 30, 2025	165,069,647	$2		$789,720	$104		$(682,437)		$107,389

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share data)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	Income (Loss)	Deficit	Deficit
Balance at December 31, 2023	67,310,838	$1	$675,905	$95	$(723,448)	$(47,447)
Exercise of stock options and release of RSUs	826,797	—	174	—	—	174
Stock-based compensation	—	—	1,907	—	—	1,907
Other comprehensive loss	—	—	—	(105)	—	(105)
Net income	—	—	—	—	13,791	13,791
Balance at March 31, 2024	68,137,635	$1	$677,986	$(10)	$(709,657)	$(31,680)
Exercise of stock options and release of RSUs	12,477	—	20	—	—	20
Issuance of common stock under the ESPP	196,930	—	236	—	—	236
Issuance of common stock under the Open Market Sale Agreement, net of issuance cost	2,270,608	—	4,843	—	—	4,843
Exercise of pre-funded warrants	7,499,951	—	—	—	—	—
Stock-based compensation	—	—	1,882	—	—	1,882
Other comprehensive income	—	—	—	6	—	6
Net loss	—	—	—	—	(6,534)	(6,534)
Balance at June 30, 2024	78,117,601	$1	$684,967	$(4)	$(716,191)	$(31,227)
Release of RSUs	115,000	—	—	—	—	—
Stock-based compensation	—	—	1,995	—	—	1,995
Other comprehensive income	—	—	—	44	—	44
Net income	—	—	—	—	5,736	5,736
Balance at September 30, 2024	78,232,601	$1	$686,962	$40	$(710,455)	$(23,452)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.